Ignacio Torres-Navarro

Hospital Universitari i Politècnic la Fe · Dermatology

Several studies have focused on identifying microRNAs involved in the pathogenesis of melanoma. However, its association with clinicopathological features has been scarcely addressed. The aim of this study is to identify microRNAs expression profiles related to aggressive clinicopathological and molecular features, and to analyze the association wi...

Epidermal necrolysis (EN) compromises a spectrum of life‐threatening dermatoses (Stevens–Johnson Syndrome [SJS], overlap syndrome and toxic epidermal necrolysis [TEN]). Currently, no active therapeutic regimen with unequivocal benefit exists for SJS/TEN. SCORTEN is the widely‐used prognostic scale specific for SJS/TEN. Nevertheless, a new prognosti...

Severe Cutaneous Adverse Reactions (SCARs) [Stevens‐Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Rash with Eosinophilia and Systemic Syndrome (DRESS), Acute Generalized Exanthematous Pustulosis (AGEP), and Generalized Bullous Fixed Eruption (GBFE)] are severe drug reactions that often require hospitalization and could be fatal. BR...

Folliculocystic and collagenous hamartoma (FCCH) is a rare cutaneous manifestation characterized by the presence of single plaques studded with comedo‐like openings and cysts. Although its pathophysiology is still unknown, it has generally been described in men with tuberous sclerosis complex (TSC). We report a case of a one‐year‐old child with two...

Importance A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been identified as the cause of a pandemic called coronavirus disease 2019 (COVID-19). In this context, some associated skin diseases have been described. Cutaneous lesions referred to as acute acro-ischemia have been reported as a possibl...

Background The SCORTEN score is a specific predictor of mortality for patients with Stevens Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN). There is little evidence in support of the common immunomodulating therapies for SJS/TEN. Objectives To systematically assess the effectiveness of several therapies for SJS/TEN through the SCORTEN sco...

We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID‐19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.

Dear editor, we have read with interest Dr´s Alramthan and Aldaraji contribution to the spectrum of COVID‐19 clinical manifestations.¹ Since COVID‐19 outbreak begin, new symptoms have been described.² Some of them, were not initially highlighted and could be a distinguishing feature of COVID‐19 infection, like anosmia or ageusia.³ Therefore, it is...

Resumen Las úlceras genitales constituyen un motivo frecuente de consulta en urgencias, especialmente en ginecología. Sin embargo, debido a la baja frecuencia de algunas de ellas, junto con el amplio diagnóstico diferencial que puede plantear cada caso, hacen que el diagnóstico de dichas lesiones, en ocasiones, sea difícil o erróneo. Presentamos el...

Background The SCORTEN score is a specific predictor of the probability of death for patients diagnosed with Stevens‐Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Objectives To evaluate the overall accuracy of SCORTEN and the influence of several moderators such as age, sex, geographical region and age of the study. Methods A systemati...

Pancreatic panniculitis (PP) is an infrequent manifestation of pancreatic pathology (2%). This condition has mainly been described in association with acute and chronic pancreatitis, in males aged 40-60 years with chronic alcoholism, as was the case of this patient. However, it might also be the outset manifestation of a pancreatic neoplasm.

Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two ste...

Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two ste...